Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Disappointing study results for Conatus Pharmaceuticals By: MarketMinute.com Stock News April 05, 2018 at 18:08 PM EDT Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) reported disappointing results from a Phase 2b POLT-HCV-SVR clinical trial in liver transplant patients with fibrosis or cirrhosis. The stock price plunged $1.89 to close at $4.12. Related Stocks: Conatus Pharmaceutic Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Disappointing study results for Conatus Pharmaceuticals By: MarketMinute.com Stock News April 05, 2018 at 18:08 PM EDT Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) reported disappointing results from a Phase 2b POLT-HCV-SVR clinical trial in liver transplant patients with fibrosis or cirrhosis. The stock price plunged $1.89 to close at $4.12. Related Stocks: Conatus Pharmaceutic